Mardepodect is a CNS penetrant PDE10A inhibitor [21,22], developed by Pfizer initially for schizophrenia [23] and later repositioned for Huntington’s Chorea within the AMARYLLIS clinical trial [24]. Here, PDE10A is linked to schizophrenia.